Is this the ideal patient-payer-pharma social media convergence?

Featured Story

Is this the ideal patient-payer-pharma social media convergence?

April 16, 2014 4:38 pm by | 0 Comments

One of the dominant themes at the Eye for Pharma conference this week has been how pharmaceutical companies can use social media channels beyond just conveying a positive message about…


ASCO at work on a scoring system to weigh cost vs. potential benefits of pricey cancer treatments

ASCO at work on a scoring system to weigh cost vs. potential benefits of pricey cancer treatments

April 17, 2014 12:03 pm by | 0 Comments

Cancer doctors and patients need a better way to weigh the potential benefits of new targeted cancer treatments against their costs, especially those that carry a price tag north of…


Zogenix prevails in initial challenge to Massachusetts emergency order banning ZOHYDRO ER

Zogenix prevails in initial challenge to Massachusetts emergency order banning ZOHYDRO ER

April 17, 2014 12:59 am by | 0 Comments

 By Kurt R. Karst –   When we first heard about the Complaint and Motion for Preliminary Injunction Zogenix, Inc. filed against Massachusetts Governor Deval Patrick, among others, alleging that…



One reason to embrace shift away from healthcare’s fee-for-service model: Better drugs

One reason to embrace shift away from healthcare’s fee-for-service model: Better drugs

April 16, 2014 10:09 pm by | 1 Comments

As much as people have been talking about the upcoming shift away from the fee-for-service model of healthcare, in most cases it’s an abstract concept as it’s still years away…


Teva recalls generic version of anti-depressant Cymbalta

Teva recalls generic version of anti-depressant Cymbalta

April 16, 2014 5:02 pm by | 0 Comments

“FiercePharmaManufacturing” reports that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has recalled its generic version of anti-depressant Cymbalta, duloxetine, because of a customer complaint about capsule breakage. The voluntary…


FDA makes adverse drug event data public, but this health IT startup makes it useful

FDA makes adverse drug event data public, but this health IT startup makes it useful

April 16, 2014 3:26 pm by | 0 Comments

Four times a year, the FDA releases data about all of the adverse drug events that have been reported to the agency over a three-month time period. Drug companies are…


Abbott earnings fall in 1Q as sales lag

Abbott earnings fall in 1Q as sales lag

April 16, 2014 1:34 pm by | 0 Comments

Abbott Laboratories said Wednesday its first-quarter profit fell 31.1 percent to $375 million, or 24 cents a share, as certain one-time costs, including expenses associated with repatriating international profits, ate…


True Grit: Why pharma’s leaders aren’t yet capable

True Grit: Why pharma’s leaders aren’t yet capable

April 16, 2014 6:00 am by | 0 Comments

Faced with an ever-challenging commercial environment, how do upcoming pharma leaders stack up when it comes to critical leadership capabilities and how can they be nurtured to achieve success? “The…



Q&A with John Castellani of PhRMA

Q&A with John Castellani of PhRMA

April 15, 2014 3:57 pm by | 0 Comments

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading biopharmaceutical research and biotechnology companies. Dialogues+ had the opportunity to ask John Castellani, President and CEO of PhRMA, questions about his organization and the Physician Payments Sunshine Act….


J&J income rises 35 percent in first quarter

J&J income rises 35 percent in first quarter

April 15, 2014 11:07 am by | 0 Comments

Johnson & Johnson’s net income rose 35 percent during the first quarter thanks in part to stronger sales in its pharmaceutical division, the company said Tuesday. The New Brunswick-based health…


Zohydro ban: Disagreeing with Governor Patrick

Zohydro ban: Disagreeing with Governor Patrick

April 15, 2014 8:01 am by | 1 Comments

Massachusetts Governor Deval Patrick is trying to ban Zohydro ER, a new prescription painkiller, under a state of emergency he’s declared to combat opiate abuse. I agree with the Governor…


What’s the impact of ACA on medication costs? IMS Health report offers some clues

What’s the impact of ACA on medication costs? IMS Health report offers some clues

April 15, 2014 7:11 am by | 0 Comments

The Affordable Care Act and innovative biotech trends are having an impact on medication costs and healthcare spend generally, according to a new report by the IMS Health Institute for…


Provectus Biopharmaceuticals signs with Chinese firm to find licensing partner

Provectus Biopharmaceuticals signs with Chinese firm to find licensing partner

April 15, 2014 6:45 am by | 0 Comments

Knoxville-based Provectus Biopharmaceuticals has signed with an investment banking firm in China to help identify distribution and joint venture partners for the company’s oncology drug PV-10. Shanghai-based Tririver Capital Co.,…


Glenmark receives $5 million milestone payment from Sanofi

Glenmark receives $5 million milestone payment from Sanofi

April 15, 2014 3:53 am by | 0 Comments

MUMBAI — Drug maker Glenmark Pharmaceuticals Ltd said on Tuesday that its new drug candidate for the treatment of autoimmune disorder has achieved another milestone towards final stage of discovery….


Scripps, Johnson & Johnson join forces in drug development effort

Scripps, Johnson & Johnson join forces in drug development effort

April 14, 2014 10:46 am by | 0 Comments

JUPITER — In an effort to spur start-up biotech companies, Scripps Florida said Monday that it has created a new venture and has partnered with a big-name drug firm. The…


High cost of potent Hepatitis drug presents challenges across the U.S.

High cost of potent Hepatitis drug presents challenges across the U.S.

April 14, 2014 9:39 am by | 0 Comments

Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since, it won federal approval in December, lawmakers, insurers and patient advocates have begun…